Evidence map›Paper›PMID 41968947›Full record

ArticleBritish journal of haematology2026

Deciphering the full spectrum of Castleman diseases based on a cohort of 700 patients in a western country.

Eric Oksenhendler, Marion Malphettes, Véronique Meignin, David Boutboul, Lionel Galicier

Abstract read
In one paragraph

Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Eric OksenhendlerDepartment of Clinical Immunology, Hôpital Saint-Louis, AP-HP, Paris, France.ORCID https://orcid.org/0000-0001-8588-7138
Marion MalphettesDepartment of Clinical Immunology, Hôpital Saint-Louis, AP-HP, Paris, France.ORCID https://orcid.org/0000-0002-9888-2528
Véronique MeigninFrench National Reference Center for Castleman Disease, Paris, France.ORCID https://orcid.org/0000-0003-0502-9489
David BoutboulDepartment of Clinical Immunology, Hôpital Saint-Louis, AP-HP, Paris, France.
Lionel GalicierFrench National Reference Center for Castleman Disease, Paris, France.

Funding

Ministry of HealthRare Diseases National Plan
6 · The paper itself

Abstract

Under the Castleman disease (CD) eponym, three distinct diseases sharing common pathological features have been described over time. Using the French national registry for CDs, we revisited the full spectrum of these diseases to update our current knowledge on the optimal management of these patients. The unicentric type (UCD) has usually an indolent course and can be cured by surgical resection. However, a small percentage of the UCD patients develop severe autoimmune or malignant complications. The human herpesvirus 8 (HHV8)-associated multicentric type (HHV8+ MCD) has been mainly described in human immunodeficiency virus (HIV)-infected patients but is an emerging condition outside this setting in other populations. The third type, idiopathic multicentric Castleman disease (iMCD) remains a challenging diagnosis as the pathological features observed in these patients are shared with many other conditions such as lymphoid neoplasia and systemic diseases. Other syndromes such as POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes), TAFRO (thrombocytopenia, anasarca, myelofibrosis, renal dysfunction and organomegaly), IgG4-RD (IgG4-related disease) and IPL (idiopathic plasmacytic lymphadenopathy) may also overlap with iMCD and could be considered either associated conditions or differential diagnosis. In addition, the clinical phenotype of iMCD exhibits several striking differences among populations with a much more heterogeneous pattern in Western populations than in patients of Asian ancestry.

Indexed as

Castleman DiseaseAdultAgedCohort StudiesFemaleFranceHerpesvirus 8, HumanHumansMaleMiddle AgedRegistriesCastleman diseaseHHV8IgG4‐RDiMCDIPLlymphadenopathyPOEMSTAFRO

Identifiers

PMID41968947
PMCPMC13267460

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.